Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
55 studies found for:    ac-220
Show Display Options
Rank Status Study
1 Completed Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
Condition: Acute Myeloid Leukemia
Intervention: Drug: Compound AC220
2 Completed A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Conditions: Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: AC220;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Methotrexate
3 Active, not recruiting Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: Compound AC220
4 Completed A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.
Conditions: Acute Myeloid Leukaemia;   High Risk Myelodysplastic Syndrome
Interventions: Drug: Plerixafor;   Drug: AC220;   Drug: Ganetespib
5 Completed A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Conditions: Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndrome;   AML;   MDS
Intervention: Drug: AC220
6 Recruiting AC220 With 5-Aza or Low Dose Cytarabine
Condition: Leukemia
Interventions: Drug: Quizartinib;   Drug: Cytarabine;   Drug: AZA
7 Active, not recruiting A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute,
Intervention: Drug: AC220
8 Completed A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: AC220;   Drug: daunorubicin;   Drug: cytarabine
9 Active, not recruiting Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: AC220
10 Recruiting An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects
Condition: AML
Interventions: Drug: Quizartinib;   Drug: Salvage Chemotherapy
11 Not yet recruiting Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations
Conditions: Acute Myeloid Leukaemia;   Myelodysplastic Syndrome
Interventions: Drug: Arm A Mylotarg;   Drug: Arm D Cladribine;   Drug: AC220;   Drug: Ganetespib
12 Recruiting Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia
Condition: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Interventions: Other: laboratory biomarker analysis;   Drug: quizartinib;   Drug: sorafenib tosylate
13 Recruiting Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers
Condition: Malaria
Interventions: Drug: MMV390048 5mg;   Drug: MMV390048 20mg;   Drug: MMV390048 60mg;   Drug: MMV390048 120mg;   Drug: MMV390048 220mg;   Drug: MMV390048 340mg;   Drug: MMV390048 475mg;   Drug: Placebo to match MMV390048;   Drug: MMV390048 x mg
14 Completed
Has Results
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
Condition: Acute Coronary Syndrome
Interventions: Drug: Clopidogrel;   Drug: Prasugrel;   Drug: Commercially-available Aspirin
15 Completed The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
Condition: Acute Coronary Syndrome
Interventions: Drug: Darapladib 160 mg;   Drug: Placebo;   Other: Standard Therapy
16 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo
17 Active, not recruiting Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Condition: Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Interventions: Drug: OSI-906;   Drug: erlotinib;   Drug: placebo
18 Completed
Has Results
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
Condition: Chronic Primary Insomnia
Interventions: Drug: almorexant;   Drug: Placebo;   Drug: zolpidem
19 Active, not recruiting Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Condition: Chronic Hepatitis B
Interventions: Drug: entecavir;   Drug: Other anti-HBV medication
20 Completed
Has Results
Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: EFI/ACT-385781A

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years